摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-庚氧基苯异氰酸酯 | 55792-37-5

中文名称
4-庚氧基苯异氰酸酯
中文别名
——
英文名称
1-(heptyloxy)-4-isocyanatobenzene
英文别名
4-(heptyloxy)phenyl isocyanate;4-heptyloxyphenyl isocyanate;1-heptoxy-4-isocyanatobenzene
4-庚氧基苯异氰酸酯化学式
CAS
55792-37-5
化学式
C14H19NO2
mdl
MFCD00673053
分子量
233.31
InChiKey
KJMZSDMQWFWLCX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    108 °C0.2 mm Hg(lit.)
  • 密度:
    1.007 g/mL at 25 °C(lit.)
  • 闪点:
    >230 °F
  • 稳定性/保质期:
    遵照规定使用和储存,则不会分解。

计算性质

  • 辛醇/水分配系数(LogP):
    5.7
  • 重原子数:
    17
  • 可旋转键数:
    8
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    38.7
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xn
  • 安全说明:
    S26,S36
  • 危险类别码:
    R20/21/22,R36/37/38
  • 海关编码:
    2929109000
  • 危险品运输编号:
    UN 2206 6.1/PG 3

SDS

SDS:f0e7002a4056dc3f9414a6965230ac0b
查看

反应信息

  • 作为反应物:
    描述:
    4-庚氧基苯异氰酸酯(R)-氨基肉碱甲醇 为溶剂, 反应 48.0h, 生成 (R)-4-trimethylammonium-3-[[4-(heptyloxy)phenyl]carbamoyl]aminobutyrate
    参考文献:
    名称:
    氨基肉碱尿苷衍生物作为肉碱棕榈酰转移酶I的抑制剂
    摘要:
    合成了氨基肉碱尿素衍生物,并将其评估为肝异构体选择性肉碱棕榈酰转移酶(CPT)I抑制剂。鉴定出的最有趣的分子(3),相应的phospho类似物(4)在体外和体内均显示出比先前鉴定出的化合物1(teglicar,ST1326)更高的功效。
    DOI:
    10.1002/cmdc.200900535
  • 作为产物:
    描述:
    4-正庚氧基苯甲酸叠氮磷酸二苯酯三乙胺 作用下, 以 甲苯 为溶剂, 反应 1.17h, 生成 4-庚氧基苯异氰酸酯
    参考文献:
    名称:
    氨基甲酸酯肟—发现一系列新型FAAH抑制剂
    摘要:
    一系列新的肟氨基甲酸酯已被确定为内源性大麻素信号系统关键调节酶脂肪酸酰胺水解酶(FAAH)的有效抑制剂。在这封信中,介绍了这种新型FAAH抑制剂的发现和生物学评估背后的原理。讨论了选定靶标的体外和体内结果,以及抑制动力学和分子模型研究。1个
    DOI:
    10.1016/j.bmcl.2009.11.080
点击查看最新优质反应信息

文献信息

  • Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof
    申请人:JAEHNE Gerhard
    公开号:US20110046185A1
    公开(公告)日:2011-02-24
    The invention relates to compounds of formula (I) wherein the groups R and R′ A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.
    该发明涉及式(I)的化合物,其中基团R和R′ A、D、E、G、L、p以及R1到R10具有所述含义,以及它们的生理相容盐。所述化合物适用于例如作为抗肥胖药物。
  • [EN] GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS<br/>[FR] DÉRIVÉS DE GALACTOPYRANOSYLE UTILES EN TANT QUE MÉDICAMENTS
    申请人:UNIV GENT
    公开号:WO2014001204A1
    公开(公告)日:2014-01-03
    This invention relates to carbamate-containing or thiocarbamate-containing galacto-pyranosyl compounds useful as therapeutic agents and being represented by the structural formula (II), wherein: X is O or S, R is selected from the group consisting of C1-8 alkyl, C3-10 cycloalkyl, aryl-C1-4 alkyl, heterocyclyl-C1-4 alkyl, cycloalkyl-C1-4 alkyl, aryl and heterocyclyl, wherein R is optionally substituted with one or more R9; R2, R3, R4, R6 and R7 are independently selected from the group consisting of hydroxyl and protected hydroxyl groups; R5 is selected from the group consisting C6-30 alkyl and arylalkyl; R8 is C6-30 alkyl; and each R9 is independently selected from the group consisting of halogen, hydroxy, trifluoromethyl, trifluoromethoxy, C1-8 alkoxy, C1-6 alkyl, cyano, methylthio, phenyl, phenoxy, chloromethyl, dichloromethyl, chloro-difluoromethyl, acetyl, nitro, benzyl, heterocyclyl and di-C1-4 alkyl-amino, or a pharmaceutically acceptable salt thereof.
    这项发明涉及含有碳酸酯或硫代碳酸酯的半乳糖基化合物,可作为治疗剂,并由结构式(II)表示,其中:X为O或S,R从以下组中选择:C1-8烷基、C3-10环烷基、芳基-C1-4烷基、杂环基-C1-4烷基、环烷基-C1-4烷基、芳基和杂环基,其中R可选择性地被一个或多个R9取代;R2、R3、R4、R6和R7独立地选自羟基和保护羟基基团;R5选自C6-30烷基和芳基烷基;R8为C6-30烷基;每个R9独立地选自卤素、羟基、三氟甲基、三氟甲氧基、C1-8烷氧基、C1-6烷基、氰基、甲硫基、苯基、苯氧基、氯甲基、二氯甲基、氯二氟甲基、乙酰基、硝基、苄基、杂环基和二C1-4烷基氨基,或其药用可接受盐。
  • Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof
    申请人:Jaehne Gerhard
    公开号:US20110112097A1
    公开(公告)日:2011-05-12
    The invention relates to compounds of formula (I) wherein the groups R and R′, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.
    该发明涉及式(I)的化合物,其中基团R和R'、A、D、E、G、L、p以及R1到R10具有所述含义,以及它们的生理相容盐。所述化合物适用于作为抗肥胖药物。
  • Protonation activates anion binding and alters binding selectivity in new inherently fluorescent 2,6-bis(2-anilinoethynyl)pyridine bisureas
    作者:Calden N. Carroll、Orion B. Berryman、Charles A. Johnson、Lev N. Zakharov、Michael M. Haley、Darren W. Johnson
    DOI:10.1039/b901643k
    日期:——
    A new class of 2,6-bis(2-anilinoethynyl)pyridine-based bisureas forms 1 : 1 complexes with halides; protonation enhances binding by over one order of magnitude, alters the binding selectivity, and provides a colorimetric indication of anion binding.
    一类新的基于2,6-双(2-苯胺基乙炔基)吡啶的Bisureas与卤化物形成1:1络合物。质子化将结合提高一个数量级,改变结合选择性,并提供阴离子结合的比色指示。
  • Urea Derivative
    申请人:Kurata Hitoshi
    公开号:US20070249620A1
    公开(公告)日:2007-10-25
    The present invention relates to a urea derivative or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect. A urea derivative having the formula: [wherein R 1 is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; R is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; E is a group having the formula (II) or the formula (III) (wherein R 3 is a hydrogen atom or others; R 4 and R 5 , which are the same or different, are a hydrogen atom or others; X and U, which are the same or different, are a group represented by the formula CH or others; m and n, which are the same or different, are I or another number) or others; and A is a group represented by the formula —NH—C(═O)— or others], or a pharmacologically acceptable salt thereof.
    本发明涉及一种具有出色DGAT抑制作用的脲衍生物或其药理学上可接受的盐。其中,该脲衍生物具有以下公式:[式中,R1是C6-C10芳基,可以独立地被来自置换基团a或其他的基团单独到五重取代;R是C6-C10芳基,可以独立地被来自置换基团a或其他的基团单独到五重取代;E是具有公式(II)或公式(III)的基团(其中,R3是氢原子或其他;R4和R5相同或不同,是氢原子或其他;X和U相同或不同,是由公式CH或其他表示的基团;m和n相同或不同,是I或其他数字)或其他;A是由公式—NH—C(═O)—或其他表示的基团],或其药理学上可接受的盐。
查看更多